Mitiglinide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mitiglinide
Mitiglinide.svg
Clinical data
Trade namesGlufast
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth (tablets)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol
3D model (JSmol)
 ‹See TfM›☒N☑Y (what is this?)  (verify)

Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology[edit]

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage[edit]

Mitiglinide is delivered in tablet form.

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
  2. ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. Archived from the original on 2015-09-24.

External links[edit]